Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.